Cancer News and Research

Latest Cancer News and Research

Celgene to initiate apremilast Phase III placebo-controlled trial for ankylosing spondylitis

Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced data from a Phase II study of apremilast, its investigational oral immunomodulatory compound, in patients with ankylosing spondylitis (AS) were presented at the American College of Rheumatology Scientific Meeting in Chicago, IL.

9 Nov 2011

Strong clean indoor air laws associated with voluntary smokefree home rules

Second hand smoke exposure among nonsmokers has declined over time as clean indoor air laws have been adopted. However, there has been concern that such laws might encourage smokers to smoke more in their homes or other private venues. Children living in a home with an adult smoker are up to twice as likely to take up smoking themselves.

9 Nov 2011

Role of Vitamin D in preventing heart disease in children both HIV-positive and HIV-negative

While Vitamin D is essential for proper bone health, a number of research studies have linked it to guarding against cardiovascular disease and certain cancers. It is unique among vitamins in that it is made by the body in response to sunlight but is naturally present in very few foods. Recent studies have confirmed that vitamin D deficiency is common, even in sunny states such as Florida.

9 Nov 2011

Insulin resistance associated with cortical atrophy and brain dysfunction

Many complications of diabetes, including kidney disease, foot problems and vision problems are generally well recognized. But the disease's impact on the brain is often overlooked.

9 Nov 2011

More than 3 million Americans quit smoking every year

The United States is winning the war against smoking. More than 3 million Americans quit smoking every year and fewer are adopting the unhealthy and expensive habit.

9 Nov 2011

Johns Hopkins researchers unravel how breast cancer metastasizes

The spread of breast cancer is responsible for more than 90 percent of breast cancer deaths. Now, the process by which it spreads—or metastasizes—has been unraveled by researchers at Johns Hopkins. Reporting in two papers, the researchers have discovered the switch that enables breast cancer cells to travel to and be received in the lungs.

9 Nov 2011

Infinity third quarter total revenue increases marginally to $23.3 million

Infinity Pharmaceuticals, Inc. today highlighted its recent clinical and business progress and announced its third quarter 2011 financial results.

9 Nov 2011

First-ever phase 1 clinical trial of rectal HIV-prevention drug

A topically applied microbicide gel containing a potent anti-HIV drug has been found to significantly reduce infection when applied to rectal tissue that was subsequently exposed to HIV in the laboratory, according to a new study by the UCLA AIDS Institute.

9 Nov 2011

Salix third quarter total product revenue increases 81% to $146.2 million

Salix Pharmaceuticals, Ltd. today announced financial and operating results for the third quarter ended September 30, 2011 and other business updates.

9 Nov 2011

Viagra may improve antitumor immunity in people with melanoma

At first it sounds like good news: The body's own immune system gets active in almost every cancer - however, not necessarily for the benefit of the patient. "We distinguish between two different types of immune response," says Professor Dr. Viktor Umansky, immunologist at DKFZ and University Medical Center Mannheim. "On the one hand, cells of the immune system specifically attack tumor cells.

9 Nov 2011

BioTime third quarter revenue increases 40% to $1.1 million

BioTime, Inc., a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the third quarter and nine months ended September 30, 2011 and highlighted recent corporate accomplishments.

9 Nov 2011

Semtech to donate $25,000 for new UCLA cancer treatment center

Semtech Corporation, a leading supplier of analog and mixed-signal semiconductors, today announced it will contribute $25,000 to the UCLA Hospital System toward the development of a new treatment center at the Ronald Reagan UCLA Medical Center for teen and young adult cancer patients.

9 Nov 2011

Viewpoints: Today's 'personhood' vote in Miss.; reactions to Romney's health care plan

What about in vitro fertilization, a process that both creates and discards embryos? What new rights would be afforded to a fetus, and how would those rights affect or compete with the rights of the woman who carries it? Would a woman who has an abortion be guilty of murder and subject to capital punishment? ... In their quest to ban abortion in Mississippi, the amendment's drafters appear to have rushed past such concerns.

9 Nov 2011

CytRx reports net loss of $0.6 million for third quarter 2011

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the three months and nine months ended September 30, 2011, and provided a business update.

9 Nov 2011

Interim data from Cytheris CYT107 Phase I/IIa combination study on HCV

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE 2 Phase I/IIa study indicate that treatment with four weeks of the Company's investigative immune-modulator, recombinant human Interleukin-7, added to peginterferon and ribavirin in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC, induces a broad immune response associated with HCV viral clearance in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC.

9 Nov 2011

Micromet third quarter total revenues decrease to $4.5 million

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the third quarter and nine months ended September 30, 2011.

9 Nov 2011

FDA accepts Genentech's vismodegib NDA for review

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed for review Genentech's new drug application (NDA) for vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.

9 Nov 2011